Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)
The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.
Inclusion Criteria:
Exclusion Criteria:
Loma Linda, California 92354, United States
New Haven, Connecticut 06520, United States
Iowa City, Indiana 52242, United States
Springfield, Massachusetts 01107, United States
Detriot, Michigan 48202, United States
Philadelphia, Pennsylvania 19102, United States
Buenos Aires, Buenos Aires C1155APP, Argentina
Capital Federal, Buenos Aires C1425APQ, Argentina
Innsbuck, 6020, Austria
Rio de Janeiro / Rj, Rio de Janeiro 21041, Brazil
Porto Alegre/rs, Rio Grande do Sul 90035, Brazil
Sao Paulo/sp, São Paulo 04038, Brazil
Gujarat, Ahmedabad 380016, India
Distrito Federal, Mexico City 14080, Mexico